Indian regulators OK Glenmark Generics spinoff; Simcere: Workers at new Chinese plant in criminal probe;

 @FiercePharma: Novartis faces lawsuit from female sales reps. Article | Follow @FiercePharma

> The Securities and Exchange Board of India has approved a planned, $142.3 million initial public offering of Glenmark Generics, a wholly-owned subsidiary of Glenmark Pharmaceuticals, sources tell the Economic TimesReport

> Biotechs cater to the most creative scientists. Report

> Simcere Pharmaceutical disclosed that employees at its recently acquired Jiangsu Yanshen vaccine producer are under criminal investigation for allegedly covering up manufacturing screw-ups that led to the release of substandard human rabies vaccine doses two years ago. Report

> Tufts: Regulatory affairs' rising workload needs attention ASAP. Report

> Hikma has inked a deal to take full control of its Algerian joint venture in a $18.5 million transaction designed to continue its expansion in the region. Report

> Merck KGaA, the German drugmaker that bought Millipore, will finish syndicating 1 billion euros ($1.3 billion) of loans this week in the first acquisition financing for a listed company this year. Report

> Monsanto says it has completed its purchase of the Chesterfield Village Research Center in Chesterfield, Mo., from Pfizer. Report

> Efforts to attract large foreign companies to take the place of AstraZeneca's massive site in Leicestershire, England, could be seriously hampered by a new tax on the rich, local business leaders said. Report

> The board of United Drug has appointed Chris Brinsmead, a former AstraZeneca U.K. executive, as a non-executive director of the company. Report

> Mylan Pharmaceuticals won the final FDA nod for its version of Braintree Laboratories' NuLytely laxative. Release

> Aurobindo Pharma got final FDA approval for five dosage strengths of its version of Wyeth's antidepressant drug Effexor. Report

Biotech News

 @FierceBiotech: Sanofi opens R&D center in China. Article | Follow @FierceBiotech

 @JohnCFierce: Tengion IPO on Friday prices at $5, closes at 5.02. High risk, no revenue not what investors are looking for these days. | Follow @JohnCFierce

> Vernalis CEO insists he's hunting for new drug deals. Story

> Jackson Lab plots new Florida genomics research center. Item

> Struggling Canadian biotechs urged to look south for cash. Article

> Javelin jilts Myriad in favor of Hospira's $141M takeover offer. Story

Biotech IT

> iPad hosts Nextrials platform. Report

> Cancer center evaluates EDC solutions, picks Medidata Rave. Story

> ClearTrial targets site, trial costs in product upgrade. Item

And Finally... A new one-off treatment that could potentially "switch off" rheumatoid arthritis is to be tested by British scientists. Report